肿瘤细胞治疗研究
ALL SOURCES
Dual CAR-NK cells targeting PD-L1 and ErbB2 (HER2) exhibit cooperative CAR signaling and counteract solid tumor heterogeneity.
同时靶向 PD-L1 与 ErbB2 可通过对抗原异质性提供抵抗力并经协同激活放大抗肿瘤信号，增强 CAR-NK 细胞对难治性实体瘤的疗效。
Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.
这些发现为靶向胶质母细胞瘤和其他实体瘤的多模式免疫治疗建立了一个有前景的平台。
IL-15 boosts mesothelin- and CD70-CAR NK cell potency in PDAC without added benefit from dual targeting.
这些发现凸显了双靶向策略的局限性，并强调了在PDAC微环境中，需要先进的工程策略来改进CAR NK细胞，而不仅限于抗原靶向和细胞因子支持。
Enhanced PD-L1 targeting boosts the cytotoxic activity of FOLR1- CAR NK92 cells against ovarian cancer.
本研究开发的串联双特异性 CAR-NK92 细胞代表了免疫治疗领域的一项有意义进展。
BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.
HLA-G 被认为是一种免疫检查点蛋白和肿瘤相关抗原。
GPC3 chimeric antigen receptor (CAR)-NK cells combined with Enoblituzumab enhance the anti-tumor efficacy against hepatocellular carcinoma.
我们的发现表明，同时靶向 GPC3 和 B7H3 可有效增强 NK 细胞介导的抗肿瘤活性。
Bispecific CAR T and CAR NK cells in dual-threat immunotherapy: opportunities and challenges.
抗原逃逸和瘤内异质性仍是基于嵌合抗原受体（CAR）的肿瘤免疫治疗实现持久缓解的主要障碍。
A phase I trial of combination CAR-NK92MI immunotherapy by dual targeting MUC-1 and PD-L1 for patients with relapsed or refractory solid tumors: focus
我们的结果表明，MUC-1 与 PD-L1 联合靶向的 CAR-NK92MI 细胞疗法是治疗伴转移的复发/难治性非小细胞肺癌患者的安全有效方法。
Correction: CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.
CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models.
我们证实，dtCAR的表达增强了NK92细胞在体外和体内的活化和杀伤能力，这为使用NK定制的CAR工程化NK92细胞治疗人肺癌提供了一种新的免疫治疗策略。
MEMBER ACCOUNT
登录成功会直接打开下一页。
